Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1623 1693
This examiner grants 41% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18249515 | COMPOSITIONS AND METHODS FOR TREATING ISCHEMIC CONDITIONS | Non-Final OA | The Regents of the University of California |
| 19237691 | FLAVONOID-CONTAINING COMPOSITIONS AND TREATMENT OF VIRAL DISEASES WITH SAME | Non-Final OA | AMH Biotech LLC |
| 19198975 | COMBINATION THERAPY USING A CD47-SIRP alpha BLOCKING AGENT AND AZACITIDINE | Final Rejection | Aurigene Oncology Limited |
| 17597405 | PREPARATION METHOD FOR SAMPLE TO BE ANALYZED, ANALYSIS METHOD, AND KIT FOR PREPARATION OF SAMPLE TO BE ANALYZED | Final Rejection | SHIMADZU CORPORATION |
| 18252502 | COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONS | Final Rejection | Beth Israel Deaconess Medical Center, Inc. |
| 18099749 | BIOSYNTHETIC HEPARIN | Non-Final OA | Rensselaer Polytechnic Institute |
| 17768145 | ENGINEERED ANTIBODIES AS MOLECULAR DEGRADERS THROUGH CELLULAR RECEPTORS | Non-Final OA | YALE UNIVERSITY |
| 17654984 | ENGINEERED ANTIBODIES AS MOLECULAR DEGRADERS THROUGH CELLULAR RECEPTORS | Non-Final OA | YALE UNIVERSITY |
| 18065228 | REELIN/VEGF-C PRODUCTION/ACTIVATION PROMOTER AND SKIN EXTERNAL COMPOSITION USING THE SAME | Non-Final OA | AMOREPACIFIC CORPORATION |
| 17913587 | COMPOSITION WHICH IS FOR TREATING OR PREVENTING RENAL CELL CANCER AND CONTAINS D-ALLOSE AS ACTIVE INGREDIENT, AND METHOD FOR TREATING OR PREVENTING CANCER USING SAME | Final Rejection | SETOLAS HOLDINGS, INC. |
| 18422936 | Sulfated Glycosaminoglycan Biomaterials as Proteoglycan Mimics | Final Rejection | Glycologix, Inc. |
| 17774888 | Liquid Pharmaceutical Composition of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine | Final Rejection | Daewoong Pharmaceutical Co., Ltd. |
| 17793635 | METHOD AND KIT FOR DNA ISOLATION | Non-Final OA | GLOBAL LIFE SCIENCES SOLUTIONS GERMANY GMBH |
| 17617439 | TREATMENTS OF HEREDITARY ANGIOEDEMA | Final Rejection | KALVISTA PHARMACEUTICALS LIMITED |
| 17616584 | ADJUVANTS FOR IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | UNIVERSITY OF MARYLAND, BALTIMORE |
| 18333057 | METHODS OF MANUFACTURING A HIGH MOLECULAR WEIGHT HEPARIN COMPOUND | Final Rejection | NexEos Diagnostics, Inc. |
| 17912799 | USE OF ASTRAGALUS MEDICINAL COMPOSITION FOR PREPARING DRUG FOR ENHANCING CANCER THERAPY | Final Rejection | PHYTOHEALTH CORPORATION |
| 18143457 | THERAPEUTIC AGENTS AND METHODS | Non-Final OA | Pop Test Oncology LLC |
| 17927894 | COMPOSITION FOR AMELIORATION, PREVENTION OR TREATMENT OF HAIR LOSS, COMPRISING CATECHIN 7-O-beta-D-APIOFURANOSIDE AS ACTIVE INGREDIENT | Final Rejection | ANPOLY INC. |
| 17998485 | USE OF COMPOUNDS FOR TREATING VIRAL INFECTIONS | Final Rejection | GODAVARI BIOREFINERIES LIMITED |
| 17887129 | COMPOSITION OF HYALURONIC ACID AND USE ALONE AND IN COMBINATION WITH RETINOIDS TO IMPROVE SKIN | Final Rejection | RoC OPCO LLC |
| 17787131 | SYNTHESIS OF LACTONE DERIVATIVES AND THEIR USE IN THE MODIFICATION OF PROTEINS | Non-Final OA | GENIE BIOTECH UK LTD. |
| 17781318 | BIODEGRADABLE POLYMERIC COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF | Final Rejection | B.G. NEGEV TECHNOLOGIES AND APPLICATION LTD., AT BEN-GURION UNIVERSITY |
| 17614407 | A MEDICAMENT FOR TREATING MYCOBACTERIAL INFECTION CHARACTERIZED BY COMBINING A CYTOCHROME bc1 INHIBITOR WITH CLARITHROMYCIN OR AZITHROMYCIN AND CLOFAZIMINE | Final Rejection | HSIRI THERAPEUTICS, INC. |
| 17435165 | 3'3'-CYCLIC DINUCLEOTIDES AND PRODRUGS THEREOF | Final Rejection | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. |
| 17269860 | PENTOSAN POLYSULFATE SODIUM PREPARATION | Final Rejection | ReqMed Company, LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy